Research programme: antibody therapeutics - Adimab/Merck & Co

Drug Profile

Research programme: antibody therapeutics - Adimab/Merck & Co

Latest Information Update: 16 Jan 2016

Price : $50

At a glance

  • Originator Adimab; Merck & Co
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 12 Jan 2016 Antibody discovery and optimisation technology licensed to Merck
  • 08 Jan 2013 Adimab and Merck expand their collaboration
  • 30 Aug 2011 Early research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top